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A B S T R A C T
Objective: Reaching a genetic diagnosis of mitochondrial disorders (MDs) is challenging due to their broad
phenotypic and genotypic heterogeneity. However, there is growing evidence that the use of whole exome
sequencing (WES) for diagnosing patients with a clinical suspicion of an MD is eﬀective (39–60%). We aimed to
study the eﬀectiveness of WES in clinical practice in Estonia, in patients with an unsolved, but suspected MD. We
also show our ﬁrst results of mtDNA analysis obtained from standard WES reads.
Methods: Retrospective cases were selected from a database of 181 patients whose ﬁbroblast cell cultures had
been stored from 2003 to 2013. Prospective cases were selected during the period of 2014–2016 from patients
referred to a clinical geneticist in whom an MD was suspected. We scored each patient according to the mi-
tochondrial disease criteria (MDC) (Morava et al., 2006) after re-evaluation of their clinical data, and then
performed WES analysis.
Results: A total of 28 patients were selected to the study group. A disease-causing variant was found in 16
patients (57%) using WES. An MD was diagnosed in four patients (14%), with variants in the SLC25A4, POLG,
SPATA5, and NDUFB11 genes. Other variants found were associated with a neuromuscular disease (SMN1,
MYH2, and LMNA genes), neurodegenerative disorder (TSPOAP1, CACNA1A, ALS2, and SCN2A genes), multi-
systemic disease (EPG5, NKX1–2, ATRX, and ABCC6 genes), and one in an isolated cardiomyopathy causing gene
(MYBPC3). The mtDNA point mutation was found in the MT-ATP6 gene of one patient upon mtDNA analysis.
Conclusions: The diagnostic yield of WES in our cohort was 57%, proving to be a very good eﬀectiveness.
However, MDs were found in only 14% of the patients. We suggest WES analysis as a ﬁrst-tier method in clinical
genetic practice for children with any multisystem, neurological, and/or neuromuscular problem, as nuclear
DNA variants are more common in children with MDs; a large number of patients harbor disease-causing var-
iants in genes other than the mitochondria-related ones, and the clinical presentation might not always point
towards an MD. We have also successfully conducted analysis of mtDNA from standard WES reads, providing
further evidence that this method could be routinely used in the future.
1. Introduction
Mitochondrial disorders (MDs) are one of the most frequent genetic
disorders, with a prevalence of ~12.5 per 100,000 in adults [1] and
∼4.7 per 100,000 in children [2]. In Estonia, the live-birth prevalence
for MDs (estimated during 2003–2009) was 1/20,764 live births [3].
However, diagnosing MDs is a very challenging task due to their ex-
tremely broad phenotypic and genotypic heterogeneity. They arise due
to a primary mitochondrial dysfunction and can aﬀect various func-
tional systems; most often the central nervous system, neuromuscular
system, and heart and liver, causing isolated or multisystemic syn-
dromes. The underlying genetic cause can be a mitochondrial DNA
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(mtDNA) point mutation, single large-scale mtDNA deletion, or a var-
iant in a nuclear gene, resulting in defective mtDNA maintenance,
transcription, protein translation, or a defective ancillary process. Of
the ∼1300 proteins in the mitoproteome encoded by nuclear DNA
(nDNA), mutations have been reported in> 250 genes [4]. Therefore,
diﬀerent scoring systems to evaluate the probability of MDs have been
developed [5–9]. These scoring systems take into account the clinical
features, biochemical changes, brain imaging anomalies, as well as
pathomorphological ﬁndings in muscle, and enzymatic changes in
muscle or ﬁbroblasts.
Nowadays, as next generation sequencing technologies become
more widely available for use in routine clinical practice, a vast number
of studies have been carried out world-wide to establish the eﬀective-
ness of whole exome sequencing (WES) for the diagnosis of diﬀerent
groups of inherited diseases. Studies on the eﬀectiveness of WES in MDs
have shown a diagnostic yield of 39–60% [10,11]. In addition, these
studies have shown that many patients suspected of having an MD,
actually have a diﬀerent disorder, usually neurological, which have
great overlap in the phenotypes. Therefore, Morava and Brown, 2015
[12] have proposed a new diagnostic algorithm – sequencing mtDNA
from blood and performing WES analysis, before taking a muscle/skin
biopsy.
Our study aimed to evaluate the diagnostic eﬀectiveness of WES in
clinical practice, in Estonia for patients with an unsolved metabolic
disease and a clinical suspicion of a mitochondrial disorder. We discuss
these patients' phenotype, results of metabolic, enzymatic, and imaging
studies, the pathomorphology of their muscle, and genotype. We also
show our ﬁrst results of mtDNA variant calling and interpretation from
standard WES reads.
2. Methods
This study was approved by the Research Ethics Committee of the
University of Tartu (approval date 17/11/2014 and number 242/M-
10). Informed consent was obtained from all patients and/or their
parents in the study group, except from those who were deceased.
2.1. Patient selection
The retrospective study group was selected from a database of 181
patients whose ﬁbroblast cell cultures had been stored in the
Department of Clinical Genetics, Tartu University Hospital, during the
period of January 2003 – December 2013. These 181 patients had been
consulted by a clinical geneticist and had a deﬁnite diagnosis or a
suspicion of a metabolic disease. The ﬁbroblasts were cultured from a
skin biopsy to carry out necessary enzyme analyses, or for future di-
agnostic purposes. At the same time in most of the cases the DNA
sample was also stored.To our study group, we included only those
patients whose physician had a strong suspicion of a MD, but previous
genetic investigations (targeted mtDNA and single nuclear gene ana-
lysis) resulted in no ﬁndings. WES analysis was not performed on any of
these patients because it was not available in Estonia prior to 2013.
The prospective study group was selected during January 2014 –
March 2016. We included patients who were referred to a clinical ge-
neticist in the Department of Clinical Genetics, Tartu University
Hospital, had an onset of the disease in childhood, and the clinical
geneticist had a clinical suspicion of an MD.
Next, we re-examined all the medical history charts of each included
patient to obtain their clinical signs and symptoms, results of metabolic
and imaging studies, and other medical investigations, including
muscle biopsy. The retrospective patients who were alive were invited
for a follow-up genetic consultation. From the patients who were de-
ceased, we had formerly taken a blood sample for DNA extraction and
their clinical history was well described. We scored each patient ac-
cording to the mitochondrial disease criteria (MDC) developed by Wolf
and Smeitink, [8] and Morava et al. [9]. WES analysis was performed
on each patient.
2.2. Whole exome sequencing
The DNA of all the patients was extracted from blood lymphocytes.
The WES analysis was carried out using diﬀerent methods due to
availability and cost-eﬀectiveness at various time points. The WES en-
richment kits used were SureSelect XT Human All Exon v5 (Patients 2,
3, 5, 6, 8, 10, 11, 12, 17, 18, and 19) or v4 (Patient 1) enrichment kit
(Agilent Technologies, Santa Clara, CA), Nextera Rapid Capture Exome
37Mb kit (Illumina Inc., San Diego, CA, USA) (Patients 4, 7, 9, 14, 15,
16, 20, 21, 22, 23, 24, 25, 26, 27, and 28), and the TruSeq Exome
Enrichment Kit 62Mb (Illumina Inc., San Diego, CA, USA) (Patient 13).
All patients were sequenced as proband only, except Patients 7 and 28,
in whom oﬀspring-parent trios were sequenced, and Patient 13 who
had two aﬀected sibs that were sequenced. After the sequencing, the
reads were aligned to hg19 reference genome using Burrows-Wheeler
Aligner (BWA) [13]. Further data processing, variant calling, and an-
notation was performed following Genome Analysis Toolkit (GATK)
best practice guidelines [14] using Picard, GATK [15,16], Annovar
[17], and SnpSift [18]. All reported variants were conﬁrmed, and fa-
milial segregation analysis was done using Sanger sequencing.
3. mtDNA analysis from standard WES reads
Every patients' reads (except patient 1) generated during standard
WES (as described in the section 2.2), but mapped to mtDNA, were
speciﬁcally analyzed to detect mtDNA variants, and to assess the fea-
sibility of investigating mtDNA from standard WES reads. In order to
study mtDNA, SAMtools [19] were used to extract reads mapped to
chrM. These reads were aligned to the b37 reference genome (GRCh37
including rCRS mitochondrial sequence) using BWA MEM [20], and
subsequently sorted and marked for duplicates by Picard. The variants
were called by combining SAMtools [19] mpileup with VarScan [21],
and then annotated using Annovar [17]. The analysis of guided variants
along with haplogroup calling was guided by Mitomap and Mitomaster
[22]. The mtDNA coverage was calculated using the GATK DepthOf-
Coverage tool.
4. Results
Out of the 181 patients in the ﬁbroblast database, we selected 21
patients for the retrospective group, of which four patients were ex-
cluded due to consent withdrawal, loss of clinical symptoms, no con-
tacts with the family and/or no stored DNA. The prospective group
consisted of 11 patients, who were all included. In total, we had 28
patients that we performed WES analysis on.
The main clinical, metabolic, imaging, and myopathological char-
acteristics of all the patients are described in the Supplementary data
(Table S1). The onset of disease ranged from prenatal to seven years of
age, with onset at birth or early infancy in the majority of patients. The
current ages ranged from 1 y to 29 y. Nine patients had deceased be-
tween the ages of 3m to 26 y. Motor developmental delay was present
in 16, and intellectual disability in 11 patients. Developmental regres-
sion was seen in three patients. Muscle weakness was evident in 16
patients. Eleven patients had muscular hypotonia and decreased/absent
deep tendon reﬂexes (DTRs), whereas 14 patients presented with
spasticity and/or elevated DTRs/positive Babinski sign. Other neuro-
logical manifestations, such as dystonia, choreoathetosis, ataxia,
tremor, nystagmus, and strabismus occurred in 18 patients. Epilepsy
was diagnosed in nine patients. The heart, vision, and gastrointestinal
system were involved in seven patients, the skeletal system in ﬁve, liver
in four, hearing in three, thyroid in two, and the peripheral nerves in
one patient. Lactate in serum and/or cerebrospinal ﬂuid was elevated in
13 patients, and tricarboxylic acid (TCA) cycle intermediates in urine
were elevated in eight patients. Brain atrophy was detected in ten
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patients, white matter injury in six, and hypo/aplasia of the corpus
callosum was found n in three patients upon MRI.
A muscle biopsy was taken from 18 patients. Unfortunately, the
SDH/COX enzyme reaction analysis, which is one of the most important
techniques to suggest a mitochondriopathy, was not performed in the
majority of cases; however, Gomori trichrome stain, NADH-TR enzyme
reaction, and electron microscopy were used to analyze the mitochon-
dria. H&E, PAS, ORO staining, nonspeciﬁc esterase, ATPase reactions,
and immunohistochemistry for alpha-4-laminin, macrophages, dystro-
phin, merosin, alpha-, beta- and gamma-sarcoglycans were also used.
We saw ragged red ﬁbers (RRF), peripheral increased staining on
Gomori trichrome or NADH-TR enzyme reaction, or mitochondrial
hyperplasia on electron microscopy in ﬁve patients. Mitochondrial ul-
trastructural changes were found in four patients. SDH/COX reaction
was performed in two patients with normal results. In addition, nine
patients had accumulations of lipid droplets in many ﬁbers.
Myoﬁbrillar disorganization was present in two patients, and dener-
vated ﬁbers were seen in one patient. Patient 4 had a characteristic
ﬁnding of spinal muscular atrophy (SMA) with large and small group
atrophy of both ﬁber types, but nearly absent COX reaction (which was
repeated and compared with a control). Patient 9 demonstrated vast
ﬁber size variability with atrophic, regenerating, and vacuolated ﬁbers,
and massive inclusions with heterogenous structure, seen using electron
microscopy. These features are very similar to the ones described by
Hedberg-Oldfors et al., [23] in patients with Vici syndrome, a new
subtype of vacuolar myopathies. Two patients did not have any pa-
thological features on muscle biopsy.
The MDC scores and grouping (deﬁnite, probable, possible, un-
likely), and the outcomes of the WES analyses are illustrated in Tables
1A and 2. We conﬁrmed disease-causing gene variants in 16 of our
patients (57%). An MD was diagnosed in four patients (14%), with
variants in the SLC25A4, POLG, SPATA5, and NDUFB11 genes. Other
variants found were associated with a neuromuscular disease (SMN1,
MYH2, and LMNA genes), a neurodegenerative disorder (TSPOAP1,
CACNA1A, and ALS2 and SCN2A genes), a multisystemic disease (EPG5,
NKX1–2, ATRX, and ABCC6 genes), and one compound heterozygous
variant in the MYBPC3 gene; an isolated cardiomyopathy-causing gene
that is typically autosomal dominant, although autosomal recessive
cases have been reported with a more severe phenotype [24], as was
the case in our Patient 28. Patient 3 had no ﬁndings on WES, but a
mtDNA point mutation was found in the MT-ATP6 gene upon sub-
sequent mtDNA sequencing analysis from frozen muscle tissue
(Table 1B).
We detected eight recurrent disease-causing variants, which have
been published before, and 19 novel variants. A detailed description of
the variants found (pathogenicity prediction according to the ACMG
guidelines [25], function of the gene, and disease causality) is given in
Table 1A-B. During our study, we have published four articles reporting
interesting cases, which provided new information on the speciﬁc dis-
ease/gene. We have described a new inheritance pattern for CACNA1A
associated disorders – autosomal recessive early onset epileptic en-
cephalopathy, progressive cerebral, cerebellar and optic nerve atrophy
with reduced lifespan [26]. In collaboration with the Wellcome Trust
Centre for Mitochondrial Research, Institute of Neuroscience, New-
castle University, UK, we have shown that autosomal dominant
SLC25A4 variants can also cause early-onset severe MD. The functional
studies on SLC25A4 variants, c.239G>A, p.(Arg80His), and
c.703C>G, p.(Arg235Gly) showed that recombinant mitochondrial
ADP/ATP carrier isoform 1 (AAC1) mutant proteins are severely im-
paired in ADP/ATP transport, most likely aﬀecting the substrate
binding and mechanics of the carrier, respectively. This highly reduced
capacity for transport probably aﬀects mtDNA maintenance and in turn
respiration, causing a severe energy crisis [27]. We have also carried
out functional studies on rat cortical neurons to elucidate the patho-
mechanisms of SPATA5 gene deﬁciency. Our results show that SPATA5
deﬁcient neurons have an imbalance in their mitochondrial fusion-
ﬁssion rate, shorter mitochondria, reduced ATP production, and shorter
axons, which means that SPATA5 defects alter the dynamics of mi-
tochondria and impair axogenesis. Therefore, SPATA5-related diseases
can be indirectly categorized under MDs [28]. In addition, we have
described a novel gene-phenotype association of biallelic mutations in
the BZRAP1 gene, causing autosomal recessive dystonia syndrome. The
delineation of the BZRAP1-associated syndrome and the results of
functional studies are shown elsewhere (manuscript in preparation).
In total, we analyzed the mtDNA of 27 patients using exome se-
quencing data. The coverage of mtDNA was highly dependent on the
enrichment kit used, thus all samples analyzed using the SureSelect
enrichment kits had markedly lower coverage. For samples sequenced
with the SureSelect kits, the 1× coverage ranged from 96.5% to 99.9%
of the mtDNA nucleotides, with one outlier of 38.3%, but the 20×
coverage ranged only from 0 to 9%. Regarding the Nextera kits, the
sequence depth of 1× was achieved in 100% of the mtDNA positions,
and the 20× coverage ranged from 63% to 100%, with 12/15 samples
achieving 20× coverage of> 95%. In two sibs sequenced using the
TruSeq kits, the 1× coverage was 100% and the 20× coverage was
51% and 76%. We detected one disease-causing variant in theMT-ATP6
gene in Patient 3, although the sample was sequenced after SureSelect
enrichment, so the coverage was lower (10 reads out of 12 supported
the variant). In case 11, a subsequent mtDNA depletion test from
muscle biopsy showed a moderately reduced mtDNA/nDNA ratio of
40% of the average ratio observed in controls. This can be classiﬁed as a
“possible” mtDNA depletion syndrome.
5. Discussion
To evaluate the eﬀectiveness of WES in Estonia, we analyzed 28
patients with a suspected MD who had been referred to a clinical ge-
neticist in the Department of Clinical Genetics, Tartu University
Hospital during the years 2003–2016. As the Department of Clinical
Genetics at Tartu University Hospital is the only clinical genetics de-
partment in Estonia, and our routine approach to patients with an un-
solved suspected mitochondrial disease is to take a skin biopsy, the
patient selection bias should be quite low. The limitations of our study
are the small sample size and the fact that we only included the patients
who had been referred to a clinical geneticist. In addition, it is im-
portant to point out, that in the retrospective study group, we pre-
liminary excluded patients whose MD has formerly been conﬁrmed by
molecular genetic studies. Therefore, this may inﬂuence the ﬁnal re-
sults.
Our results show that the eﬀectiveness of WES in patients with
suspected MD and an onset in early childhood is quite high – 57% (16/
28). However, MDs were found in only 14% (4/28) of the patients.
Nevertheless, a large proportion of the patients with clinical features
suggesting an MD, had variants in other disease-causing genes, which
mainly result in neuromuscular diseases or neurodegenerative disorders
(Table 1A). However, it is not known to us whether the mitochondrial
dysfunction in those cases is due to the primary neurological defect or a
secondary ﬁnding. Our results coincide with other studies on the ef-
fectiveness of WES in MD patients [10,11].
We also observed that the higher the MDC score, the greater the
probability of an MD (Table 2). All of the cases with a deﬁnite MDC
scoring were conﬁrmed as having an MD, except for the patient with
spinal muscular atrophy type I (SMA I). However, the MDC scoring of
the latter case was very high because the COX enzyme reaction was
nearly absent in her muscle biopsy. This resulted in an MDC score of
four points in total, but if we had not performed a muscle biopsy, the
patient would have still scored only four points, falling into the possible
MD group. Apart from the absent COX reaction, this patient had a very
typical phenotype and muscle morphotype for SMA I, but with an
atypical genotype (exon 7 and 8 deletion on one allele, and a novel
point mutation on the other allele). A recently performed systematic
review of oxidative metabolism in 24 genetically conﬁrmed SMA
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patients revealed several COX-negative ﬁbers in muscle, in all of the
cases, but it was more pronounced in SMA types I and II. In addition,
RCC enzyme activities were also reduced, and mtDNA depletion was
detected in all the patents studied [29]. However, a total absence of
COX has not been described before in SMA patients. In addition, if we
had not performed a muscle biopsy in the other three patients with the
deﬁnite scoring, all of them would have had a lower score, falling into
the probable MD group (scores 7, 6, and 6, respectively).
In the group with a probable MD scoring, the results vary widely.
Two patients were conﬁrmed to have an MD, however, here it is im-
portant to point out that muscle biopsies were not performed in these
cases. This shows that MD patients tend not to gain a deﬁnite scoring
based on clinical data and metabolic/imaging studies only. Two pa-
tients had variants in myopathy/muscular dystrophy-causing genes,
two in synaptic dysfunction-causing genes, one in an autophagy-related
gene, and one in a transcription factor encoding gene, with the latter
two causing a multisystemic disease. In the group with a possible MD
scoring, no patients were conﬁrmed to have a MD. The four conﬁrmed
cases had variants in genes with diﬀerent functions and heterogeneous
phenotypes.
Our results show that the higher the MDC scores, the more probable
it is to ﬁnd not only an MD diagnosis, but an overall genetic diagnosis
by WES analysis. Interestingly, out of 501 large gene panel sequencing
analyses carried out in a clinical setting, in our Department of Clinical
Genetics during 2015–2016, two patients not suspected of having an
MD, had a disease-causing variant in mitochondrial function related
genes (Table 1C) [30]. Their MDC scores, which were calculated
afterwards, were 7 and 4.
Among the patients with a conﬁrmed MD, the clinical symptoms
varied from motor neuron involvement (SMA I, MYH2- and LMNA-
myopathy), and other neurological signs (synaptic dysfunction), to
multisystemic involvement. However, three of the seven MD patients
presented with sensorineural hearing loss (SNHL), whereas the other
patients did not. However, this does not allow us to delineate SNHL as
being more indicative of MDs, as our study group was quite small.
Serum lactate was elevated in ﬁve of the seven MD patients, compared
to just two of the 12 patients with other diseases, suggesting that lactate
remains a good marker for MDs, although not 100% speciﬁc. However,
alanine was elevated only in one MD patient and urine organic acid
analysis was abnormal in three of the seven MD patients, whereas TCA
cycle intermediates were also elevated in patients with MYH2 and
LMNA variants. Brain MRI imaging was not very indicative, with only
brain atrophy being observed in most of the patients, including MD
patients. All these details show that we cannot clearly diﬀerentiate MDs
from other diseases on clinical grounds and metabolic/imaging studies
alone. Verity et al. [31] have also shown that children do not have
many of the symptoms that are characteristic of MD when they ﬁrst
present, and the typical features may only appear later in life. There-
fore, using WES as a ﬁrst-tier genetic analysis for patients with neuro-
muscular, neurological, and/or multisystem signs and symptoms should
be a standard protocol. This is especially true in children because re-
garding MDs, nuclear gene defects are overrepresented in pediatric
cases [4,32].
Muscle biopsy is an excellent choice for detecting mtDNA muta-
tions, deletions, and depletion [10]. Serial cryosection analysis and
respiratory chain enzyme activity analysis are also ideal for guiding
genetic studies, because muscle is aﬀected in many mitochondrial dis-
orders [4]. Indeed, muscle cryosection analysis was quite indicative in
our cohort, with all ﬁve MD patients in whom a muscle biopsy was
performed showed RRF, marked mitochondrial subsarcolemmal ag-
gregates, and/or pathological mitochondrial ultrastructure, whereas
the other patients did not. However, this is not always the case; ac-
cording to the literature, children with MDs may not always present
with RRF or abnormally structured mitochondria [33,34]. On the other
hand, a ﬁnding of mitochondriopathy in muscle could mislead us, as
there are many reports of genetically conﬁrmed neuromuscular dis-
orders with secondary mitochondriopathy [35]. Respiratory chain en-
zyme deﬁciencies can also be secondary to other various cellular pro-
cesses [36]. However, the respiratory chain enzyme activities were
normal in ﬁve of our seven MD patients, indicating that normal enzyme
analysis does not exclude an MD diagnosis. Also, because muscle biopsy
is an invasive and quite traumatizing procedure for the child and the
muscle, treating physicians, as well as parents would like to postpone it
whenever possible. There is currently a scientiﬁc debate on whether
WES analysis should precede muscle biopsy [34,37–39]. Based on our
current study, we suggest that WES is performed prior to the muscle
biopsy; however, muscle analysis might be needed afterwards for con-
ﬁrmation of the variants found, or to obtain additional information
about the patient's phenotype.
A less invasive procedure to study respiratory chain enzyme activity
is the analysis of cultured ﬁbroblast cells derived from a skin biopsy.
However, there might be cases with decreased activity in muscle, but
not in ﬁbroblasts [34], as was the case in two of our patients, 1 and 30.
For patients with no ﬁndings with WES, the next step should be
mtDNA analysis. Presently, laboratories are already working on
methods to analyze nDNA and mtDNA concomitantly from blood
lymphocytes using commercially available exome sequencing kits [40].
Dinwiddie et al. [41] have shown that using exome sequencing without
speciﬁcally enriching for mitochondrial sequences also provides suﬃ-
cient coverage for mtDNA, and both homoplasmic and heteroplasmic
mitochondrial variants may be detected. We have also developed a
bioinformatics pipeline for analyzing mtDNA from the data of whole
exome sequencing. We experienced large diﬀerences between samples,
depending on which enrichment kit was used for the WES library pre-
paration. The SureSelect kits (Agilent) had poor coverage, whereas the
Nextera and TruSeq (Illumina) had quite good coverage. However, the
SureSelect enrichment kit was used in the patient with a known mtDNA
mutation, which we also detected using the WES, despite the low
coverage. Therefore, this is a promising technique to analyze mtDNA,
without the invasive procedure of muscle or skin biopsy. However, we
should bear in mind that with this technique we analyze blood lym-
phocytes, which may not contain the mtDNA variants, especially in
patients with mitochondrial myopathy. Another bottleneck is mi-
tochondrial heteroplasmy – a low level of the variant may not be de-
tected [34]. In addition, mtDNA deletions and mtDNA depletion may be
missed. Therefore, a negative mtDNA analysis from the WES data does
not exclude the possibility of a mtDNA mutation, which can only be
achieved with certainty by examining DNA from clinically aﬀected
tissue. On the other hand, if a mutation is detected by WES, this likely
prevents the need for further (invasive) procedures. In addition, based
Table 2
The disease-causing variants found in our study group according to the mitochondrial disease criteria (MDC) grouping.
MDC grouping [9] Number of all cases/solved cases Conﬁrmed disease-causing variants
Mitochondrial function related genes Other genes
Deﬁnite (score 8–11) 4/4 SLC25A4, POLG, MT-ATP6 SMN1
Probable (score 5–7) 16/8 SPATA5, NDUFB11 MYH2, EPG5, TSPOAP1, NKX2–1, CACNA1A, LMNA
Possible (score 2–4) 7/4 ALS2, ATRX, ABCC6, SCN2A
Unlikely (score 1) 1/1 MYBPC3
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on experience from case 11, the lower coverage of mtDNA from the
WES data may indicate mtDNA depletion, which can be further in-
vestigated.
6. Conclusions
In conclusion, the eﬀectiveness of WES in Estonia for patients with a
clinical suspicion of an MD is 57%. We suggest WES analysis as a ﬁrst-
tier method in clinical genetic practice for children with any multi-
system, neurological, and/or neuromuscular problems. As nDNA var-
iants are more common in children with MDs, a large number of pa-
tients harbor disease-causing variants in genes other than
mitochondria-related ones, and the clinical presentation might not al-
ways point towards an MD. We have also successfully conducted the
analysis of mtDNA from standard WES reads, providing further evi-
dence that this method could be routinely used in the future.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgmr.2018.03.004.
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